Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fespixon (Oneness Biotech Co., Ltd., b30555)
- Development stage
- Unknown
- Lead developer
- Oneness Biotech
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Topical
01
Overview
Fespixon (ON101) is a first-in-class topical botanical cream developed by Oneness Biotech for wound healing. It is a combination product containing two active herbal extracts: 0.25% Plectranthus amboinicus extract (PA-F4) and 1% Centella asiatica extract (S1). [1, 7] The drug's mechanism of action involves modulating the wound's immune microenvironment by promoting the transition of pro-inflammatory M1 macrophages to pro-regenerative M2 macrophages, which advances the wound from the inflammatory to the proliferative stage. [1, 3, 5] Primarily developed for diabetic foot ulcers (DFUs), Fespixon has demonstrated superior complete healing rates compared to standard care in Phase 3 trials and has received marketing approval in Taiwan, Singapore, Malaysia, and China. [2, 5, 6] It is also being investigated for other indications, including a Phase 4 study for Stage 2 pressure injuries. [9]
- Brand names
- FespixonXianglei Tangzu GaoBonvadis
- Other names
- PA-F4 + S1Plectranthus amboinicus and Centella asiatica extracts
Beyond the preview
Go deeper on fespixon (Oneness Biotech Co., Ltd., b30555).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fespixon (Oneness Biotech Co., Ltd., b30555).